TIDMPXS
RNS Number : 4428R
Provexis PLC
29 June 2015
29 June 2015
Provexis plc
Fruitflow(R) and Blood Pressure - first stage update
Collaboration with University of Oslo
Provexis plc ("Provexis" or the "Company"), the business that
develops and licenses the proprietary, scientifically-proven
Fruitflow(R) heart-health functional food ingredient, is pleased to
announce an update to its collaboration agreement with the
University of Oslo, to undertake further research into the
relationship between Fruitflow(R) and blood pressure
regulation.
Recent work undertaken by the University of Oslo ('the
University') has shown that the Company's Fruitflow(R) technology
has a potential new bioactivity leading to blood pressure lowering
effects. In November 2014 the Company signed a two stage
collaboration agreement with the University, and a related option
agreement with Inven2 AS, the University's technology transfer
office, to undertake further research into the relationship between
Fruitflow(R) and blood pressure regulation.
The first stage of the collaboration work has now been
completed. First stage work focussed on developing the science,
with major areas including fractionation, testing, bioactivity,
dosage and further IP development.
The key results from this first stage have been very
encouraging, with strong evidence from the laboratory based work
that a standard 150mg dose of Fruitflow(R) in powder format has the
potential to give a clinically relevant reduction in systolic blood
pressure.
The Company and the University will now proceed with the second
stage of the collaboration work, which will see the parties conduct
a small clinical trial by way of a proof of principle study. Study
designs are currently being prepared for ethics approval before
finalisation, with a potential dosage for the study of 150mg
Fruitflow(R) in powder format twice per day.
The University of Oslo's research team is led by Professor Asim
Duttaroy, Group Leader of Chronic Disease at the Faculty of
Medicine, who was the original inventor of Fruitflow(R). Provexis'
work under the collaboration is led by Dr Niamh O'Kennedy, a
research chemist specialising in the field of natural products
chemistry who played a key role in the development of Fruitflow(R),
and the health claim for Fruitflow(R) which was adopted by the
European Food Safety Authority ('EFSA').
Dawson Buck, Chairman of Provexis, commented:
"We are very encouraged with the results from the first stage of
this laboratory based collaboration work, which suggest that a
standard dose of Fruitflow in powder format has the potential to
give a clinically relevant reduction in systolic blood pressure,
which would be of relevance to a large number of consumers and
patients with a wide range of cardiovascular conditions.
The collaboration is an important step in maximising the
opportunities available to commercialise Fruitflow, and we look
forward to continuing the development of this very promising blood
pressure lowering programme."
- ends -
For further information please contact:
Provexis plc Tel: 07917 670260
Dawson Buck, Chairman enquiries@provexis.com
Ian Ford, Finance Director
Cenkos Securities plc Tel: 020 7397 8900
Bobbie Hilliam
Notes for editors
About Provexis plc
AIM-listed Provexis is focused on the development and licensing
of its proprietary, scientifically-proven Fruitflow(R) heart-health
functional food ingredient.
In May 2009, the company's Fruitflow(R) technology was the first
to be substantiated by the European Food Safety Authority ("EFSA")
under the new Article 13(5) for proprietary and emerging science.
In December 2009 the European Commission authorised the health
claim "Helps maintain normal platelet aggregation, which
contributes to healthy blood flow", which was the first wording to
be authorised under Article 13(5).
In June 2010 it was announced that the company had entered into
a long-term Alliance Agreement with DSM Nutritional Products to
commercialise Fruitflow(R), and in June 2015 the Company confirmed
that it had agreed significantly enhanced financial terms for its
Alliance Agreement with DSM for Fruitflow(R).
The Company's Alliance partner DSM Nutritional Products has
developed the market actively for the Company's novel, patented
Fruitflow(R) heart-health ingredient in all global markets, with
over 35 regional consumer healthcare brands now having been
launched by DSM customers. DSM's total revenues for Fruitflow(R)
for the year ended 31 March 2015 grew strongly by more than 73%
year on year, reflecting strong interest in Fruitflow(R) and the
success of the powder format which is being used in an increasing
number of new product launches.
An increasing number of further commercial projects have been
initiated by DSM with prospective customers, including some
prospective customers which are part of global businesses, with
good prospects for these projects to be launched as consumer
products. Interest in the technology exists in all major global
markets.
On 4 June 2015 the Company announced that it had joined
PrimaryBid.com (www.primarybid.com), the online platform dedicated
to equity crowdfunding for AIM-listed companies.
PrimaryBid.com provides a new channel for the Company to raise
equity from investors, allowing investors to bid directly for new
shares in the Company at prices of their choosing, subject to
certain limited restrictions. Full details can be found on
www.primarybid.com.
Provexis was founded in 1999 and is headquartered in Reading,
Berkshire.
Provexis shares are traded on the AIM market of the London Stock
Exchange under the ticker symbol PXS.
For further information, please visit www.provexis.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAFKPASESEAF
Provexis (LSE:PXS)
Historical Stock Chart
From Apr 2024 to May 2024
Provexis (LSE:PXS)
Historical Stock Chart
From May 2023 to May 2024